KRAS testing on colo‐rectal carcinoma cytological imprints
- 17 March 2011
- journal article
- advances in-technology
- Published by Wiley in Diagnostic Cytopathology
- Vol. 39 (4), 274-277
- https://doi.org/10.1002/dc.21417
Abstract
Anti-EGFR monoclonal antibodies, cetuximab, and panitumumab, are administrated under the condition that advanced colo-rectal cancer (CRC) carries a wild-type KRAS gene. Thus, clinicians request pathologists to genotype KRAS before treatment. In the near future routine mutation testing at the same time of the surgery may be implemented. The reliability of a rapid KRAS testing on ex vivo cytological samples obtained by direct scraping of the colon tumour tissue is here evaluated. A consecutive series of 20 surgically resected, primary CRC specimens was analysed. Fresh tissue from CRC was scraped with a scalpel blade, smeared on uncoated glass slides, air-dried and Diff–Quik stained to ensure malignant cell presence. The same tissue area was also histologically processed. Exon 2 KRAS gene mutations were evaluated on both cytological and histological specimens by dideoxy sequencing and by the DxS KRAS Mutation Test Kit (DxS, Manchester, England). Data obtained on on imprint cytology and matched histological samples showed full concordance; however, the mutation frequency was slightly higher (35%) by the DxS KRAS Mutation Test Kit than by the dideoxy sequencing (30%). Thus, colon cancer imprint cytology sample is a reliable biospecimen for both dideoxy-sequencing and DxS KRAS Mutation Test Kit analysis and it may be useful to abbreviate the KRAS assay turnaround time. Diagn. Cytopathol. 2011;39:274–277. ©2010 Wiley-Liss, Inc.Keywords
This publication has 10 references indexed in Scilit:
- KRAS mutation analysis on cytological specimens of metastatic colo‐rectal cancerDiagnostic Cytopathology, 2010
- KRAS Genotyping of Paraffin-Embedded Colorectal Cancer Tissue in Routine Diagnostics: Comparison of Methods and Impact of HistologyThe Journal of Molecular Diagnostics, 2010
- Targeted KRAS Mutation Assessment on Patient Tumor Histologic Material in Real Time DiagnosticsPLOS ONE, 2009
- The Role of KRAS Mutation Testing in the Management of Patients With Metastatic Colorectal CancerArchives Of Pathology & Laboratory Medicine, 2009
- American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti–Epidermal Growth Factor Receptor Monoclonal Antibody TherapyJournal of Clinical Oncology, 2009
- Association of progression‐free survival, overall survival, and patient‐reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapyCancer, 2009
- KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance programVirchows Archiv, 2008
- EGFR Antagonists in Cancer TreatmentNew England Journal of Medicine, 2008
- In vitro mutation artifacts after formalin fixation and error prone translesion synthesis during PCRBMC Clinical Pathology, 2004
- Methods for detection of point mutations: performance and quality assessmentClinical Chemistry, 1997